oophorectomy

PROCEDURE10 trials

Sponsors

Cancer Research UK, Scottish Cancer Therapy Network, Institute of Cancer Research, United Kingdom, ETOP IBCSG Partners Foundation, University of Alabama at Birmingham

Conditions

Breast CancerDeleterious BARD1 Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationDeleterious BRIP1 Gene MutationDeleterious EPCAM Gene MutationDeleterious MLH1 Gene MutationDeleterious MSH2 Gene Mutation

Phase 3

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

CompletedNCT00002582

Institute of Cancer Research, United KingdomBreast Cancer

Start: 1993-06-30End: 2007-04-30Target: 6000Updated: 2013-08-02

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

CompletedNCT00066690

ETOP IBCSG Partners FoundationEstrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma +5

Start: 2003-12-17End: 2024-11-06Updated: 2026-02-06

Premenopausal Endocrine Responsive Chemotherapy Trial

TerminatedNCT00066807

ETOP IBCSG Partners FoundationBreast Cancer

Start: 2003-08-31End: 2006-12-31Updated: 2016-10-28

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

CompletedNCT00002580

Scottish Cancer Therapy NetworkBreast Cancer

Start: 1993-06-30Target: 1000Updated: 2013-11-06

Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer

Cancer Research UKBreast Cancer

Start: 1987-09-30Updated: 2013-08-07

Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer

CompletedNCT00293540

International Breast Cancer Research FoundationBreast Cancer

Start: 2006-02-28End: 2015-03-31Updated: 2016-07-27

Unknown Phase

Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy

WithdrawnNCT00084370

University of Alabama at Birminghambrca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer

Start: 2002-06-30End: 2005-03-31Updated: 2013-08-22

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Active, not recruitingNCT02760849

M.D. Anderson Cancer CenterDeleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation +11

Start: 2016-05-02End: 2041-05-31Updated: 2026-01-07

Ovarian Tissue Cryopreservation for Fertility Preservation in Girls and Women

SuspendedNCT05434936

Baylor College of MedicineFertility Preservation

Start: 2017-08-11End: 2027-10-10Target: 24Updated: 2023-06-18

Ovarian Tissue Cryopreservation in the Setting of Gender-affirming Therapy

Active, not recruitingNCT05863676

University of PittsburghGender Dysphoria, Transgender

Start: 2020-07-14End: 2030-07-31Target: 20Updated: 2025-08-07

Related Papers

Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.

2025-10-01

15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.

Journal of Clinical Oncology2025-05-288 citations

Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk.

2025-03-221 citations

Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial.

Journal of Clinical Oncology2023-06-017 citations

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

Journal of Clinical Oncology2022-12-0952 citations

P1239 Better quality of life in <i>BRCA</i> mutation carriers after salpingectomy with delayed oophorectomy compared to salpingo-oophorectomy; first results of the Dutch TUBA study

2019-11-01

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

New England Journal of Medicine2018-06-04645 citations

Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.

Journal of Clinical Oncology2018-05-2017 citations

Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

Cancer Research2018-02-1511 citations

Abstract GS4-03: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

Cancer Research2018-02-158 citations

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.

2017-09-0149 citations

Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer.

2016-04-207 citations

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

2015-06-16128 citations

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

New England Journal of Medicine2014-12-11720 citations

Comparison of Treatments for HR+ Early Breast Cancer

MD Conference Express2014-07-01

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

Journal of Clinical Oncology2014-06-2019 citations

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

New England Journal of Medicine2014-06-01738 citations

Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).

Journal of Clinical Oncology2014-05-2014 citations

Estrogen levels in premenopausal (prem) patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy.

Journal of Clinical Oncology2014-05-2011 citations

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

Journal of Clinical Oncology2014-05-2010 citations

1 more papers not shown